Linda Bosserman, MD, discusses the emerging role of telehealth and the challenges with implementing this type of care into cancer centers in the United States.
Linda Bosserman, MD, an assistant clinical professor and staff physician at the City of Hope, discusses the emerging role of telehealth and the challenges with implementing this type of care into cancer centers in the United States.
At the City of Hope, Bosserman says they had already identified the telehealth platform that they wanted to use and were integrating it into their workflow and electronic record. However, there is a whole set of steps that must take place first, such as scheduling, billing, safety, privacy, and patient education.
While it is nice that patients can use video conferencing applications at this time, telehealth platforms must be set up in a HIPPA-compliant way or they will not be the best moving forward in this setting. At this time, video conferencing, as well as phone calls, are allowed in emergency to connect physicians with their patients, address patient issues, and limit the number of patients coming into the hospital. These platforms can also be used to triage patients before coming into the center so they are brought to the safest site in which they can be seen.
Cancer centers across the United States are observing these issues now, but moving forward, Bosserman believes we will see fully integrated platforms for telehealth integrated into health records so that everything is available for an entire multidisciplinary team. Those are the long-term successes, and we have to study them to see their impact on outcomes, Bosserman concludes.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More